|
IL85035A0
(en)
|
1987-01-08 |
1988-06-30 |
Int Genetic Eng |
Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
|
|
EP1400536A1
(en)
|
1991-06-14 |
2004-03-24 |
Genentech Inc. |
Method for making humanized antibodies
|
|
DK0690873T3
(da)
|
1993-03-19 |
2003-09-29 |
Univ Johns Hopkins Med |
Vækstdifferentieringsfaktor-8
|
|
US5994618A
(en)
|
1997-02-05 |
1999-11-30 |
Johns Hopkins University School Of Medicine |
Growth differentiation factor-8 transgenic mice
|
|
ES2330062T3
(es)
|
1998-05-06 |
2009-12-03 |
Metamorphix, Inc. |
Procedimientos para tratar la diabetes por inhibicion de gdf-8.
|
|
US6927044B2
(en)
|
1998-09-25 |
2005-08-09 |
Regeneron Pharmaceuticals, Inc. |
IL-1 receptor based cytokine traps
|
|
US7056512B1
(en)
|
1999-07-20 |
2006-06-06 |
Pharmexa A/S |
Method for down-regulating GDF-8 activity
|
|
US6670140B2
(en)
|
2001-03-06 |
2003-12-30 |
The Procter & Gamble Company |
Methods for identifying compounds for regulating muscle mass or function using corticotropin releasing factor receptors
|
|
US7320789B2
(en)
|
2001-09-26 |
2008-01-22 |
Wyeth |
Antibody inhibitors of GDF-8 and uses thereof
|
|
US7241444B2
(en)
|
2002-01-18 |
2007-07-10 |
Pierre Fabre Medicament |
Anti-IGF-IR antibodies and uses thereof
|
|
AR047392A1
(es)
|
2002-10-22 |
2006-01-18 |
Wyeth Corp |
Neutralizacion de anticuerpos contra gdf 8 y su uso para tales fines
|
|
US20040101920A1
(en)
|
2002-11-01 |
2004-05-27 |
Czeslaw Radziejewski |
Modification assisted profiling (MAP) methodology
|
|
US7598227B2
(en)
|
2003-04-16 |
2009-10-06 |
Isis Pharmaceuticals Inc. |
Modulation of apolipoprotein C-III expression
|
|
BRPI0410927A
(pt)
|
2003-06-02 |
2006-06-27 |
Wyeth Corp |
métodos terapêuticos e profiláticos para distúrbios neuromusculares
|
|
CA2551877A1
(en)
|
2003-12-31 |
2005-07-21 |
Schering-Plough Ltd. |
Neutralizing epitope-based growth enhancing vaccine
|
|
EP1729793B1
(en)
|
2004-03-02 |
2015-07-22 |
Acceleron Pharma Inc. |
Alk7 and myostatin inhibitors for muscle wasting disorders
|
|
ATE557042T1
(de)
|
2004-03-23 |
2012-05-15 |
Lilly Co Eli |
Anti-myostatin-antikörper
|
|
WO2005103081A2
(en)
|
2004-04-20 |
2005-11-03 |
Genmab A/S |
Human monoclonal antibodies against cd20
|
|
AU2005272646A1
(en)
|
2004-08-12 |
2006-02-23 |
Wyeth |
Combination therapy for diabetes, obesity, and cardiovascular diseases using GDF-8 inhibitors
|
|
NZ538097A
(en)
|
2005-02-07 |
2006-07-28 |
Ovita Ltd |
Method and compositions for improving wound healing
|
|
NL1031674C2
(nl)
|
2005-04-25 |
2007-04-26 |
Pfizer |
Antilichamen tegen myostatine.
|
|
CN102321174B
(zh)
|
2005-05-06 |
2013-10-16 |
津莫吉尼蒂克斯公司 |
Il-31单克隆抗体及使用方法
|
|
EP1773041A1
(en)
|
2005-07-21 |
2007-04-11 |
Chao-Hung Wu |
Audio/video data transmission system using the internet to interconnect telephones
|
|
ES2534760T3
(es)
|
2005-08-19 |
2015-04-28 |
Wyeth Llc |
Anticuerpos antagonistas contra GDF-8 y sus usos en el tratamiento de ELA y otros trastornos asociados con GDF-8
|
|
BRPI0616923A2
(pt)
|
2005-10-06 |
2011-07-05 |
Lilly Co Eli |
anticorpos monoclonais, seus usos e composição farmacêutica
|
|
UA92504C2
(en)
|
2005-10-12 |
2010-11-10 |
Эли Лилли Энд Компани |
Anti-myostatin monoclonal antibody
|
|
US8128933B2
(en)
|
2005-11-23 |
2012-03-06 |
Acceleron Pharma, Inc. |
Method of promoting bone growth by an anti-activin B antibody
|
|
JP2009518422A
(ja)
|
2005-12-06 |
2009-05-07 |
アムジェン インコーポレイテッド |
ミオスタチン・アンタゴニストの使用
|
|
US7972599B2
(en)
|
2006-03-20 |
2011-07-05 |
University Of Pittsburgh Of The Commonwealth System Of Higher Education |
Immunomodulation of inflammatory conditions utilizing Follistatin-like protein-1 and agents that bind thereto
|
|
ES2398076T3
(es)
|
2006-06-02 |
2013-03-13 |
Regeneron Pharmaceuticals, Inc. |
Anticuerpos de alta afinidad contra el receptor de IL-6 humano
|
|
US8309068B2
(en)
|
2006-08-03 |
2012-11-13 |
Myostin Therapeutics Pty Ltd. |
Isolated polypeptides and methods of improving muscle strength
|
|
CA2661836A1
(en)
|
2006-09-05 |
2008-03-13 |
Eli Lilly And Company |
Anti-myostatin antibodies
|
|
CL2007002567A1
(es)
|
2006-09-08 |
2008-02-01 |
Amgen Inc |
Proteinas aisladas de enlace a activina a humana.
|
|
TWI573802B
(zh)
|
2007-03-06 |
2017-03-11 |
安美基公司 |
變異之活動素受體多肽及其用途
|
|
PE20091163A1
(es)
|
2007-11-01 |
2009-08-09 |
Wyeth Corp |
Anticuerpos para gdf8
|
|
EP2463282B1
(en)
|
2007-11-05 |
2013-08-07 |
Novartis AG |
4-Benzylamino-1-carboxyacyl-piperidine derivatives as CETP inhibitors useful for the treatment of diseases such as hyperlipidemia or arteriosclerosis
|
|
SMT202300222T1
(it)
|
2008-08-14 |
2023-09-06 |
Acceleron Pharma Inc |
Trappole di gdf
|
|
AR074777A1
(es)
|
2008-12-19 |
2011-02-09 |
Glaxo Group Ltd |
Proteinas de union a antigeno
|
|
US8138142B2
(en)
|
2009-01-13 |
2012-03-20 |
Acceleron Pharma Inc. |
Methods for increasing adiponectin in a patient in need thereof
|
|
JP5766179B2
(ja)
|
2009-04-27 |
2015-08-19 |
ノバルティス アーゲー |
筋肉増殖を増加させるための組成物および方法
|
|
JP5816170B2
(ja)
|
2009-06-26 |
2015-11-18 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． |
天然の免疫グロブリン形式を有する容易に単離される二重特異性抗体
|
|
JP6267425B2
(ja)
|
2009-11-17 |
2018-01-24 |
アクセルロン ファーマ， インコーポレイテッド |
筋ジストロフィー治療のためのユートロフィン誘導に関するａｃｔｒｉｉｂタンパク質およびその改変体およびその使用
|
|
JO3340B1
(ar)
|
2010-05-26 |
2019-03-13 |
Regeneron Pharma |
مضادات حيوية لـعامل تمايز النمو 8 البشري
|
|
UY33421A
(es)
|
2010-06-03 |
2011-12-30 |
Glaxo Wellcome House |
Proteinas de union al antígeno humanizados
|
|
US8999343B2
(en)
|
2010-08-16 |
2015-04-07 |
Amgen Inc. |
Antibodies that bind myostatin, compositions and methods
|
|
CN103298832A
(zh)
|
2010-11-08 |
2013-09-11 |
阿塞勒隆制药公司 |
Actriia结合剂及其用途
|
|
AU2012339722B2
(en)
*
|
2011-11-14 |
2017-09-14 |
Regeneron Pharmaceuticals, Inc. |
Compositions and methods for increasing muscle mass and muscle strength by specifically antagonizing GDF8 and/or Activin A
|
|
GR1007832B
(el)
|
2011-11-21 |
2013-02-14 |
Ιδρυμα Ιατροβιολογικων Ερευνων Ακαδημιας Αθηνων, |
Αδρανοποιητες της ακτιβινης και χρηση τους για την θεραπεια ασθενειων που σχετιζονται με παρεκκλινουσα ενεργοποιηση της "αμυντικης αποκρισης του ξενιστη"
|
|
EP2861617A1
(en)
|
2012-06-15 |
2015-04-22 |
Pfizer Inc. |
Improved antagonist antibodies against gdf-8 and uses therefor
|
|
US20150203591A1
(en)
|
2012-08-02 |
2015-07-23 |
Regeneron Pharmaceuticals, Inc. |
Mutivalent antigen-binding proteins
|
|
SG10201706148WA
(en)
|
2013-02-01 |
2017-08-30 |
Santa Maria Biotherapeutics Inc |
Administration of an anti-activin-a compound to a subject
|
|
TW201920262A
(zh)
|
2013-07-30 |
2019-06-01 |
美商再生元醫藥公司 |
抗活化素ａ之抗體及其用途
|
|
KR20160042987A
(ko)
|
2013-08-14 |
2016-04-20 |
노파르티스 아게 |
산발성 봉입체 근염을 치료하는 방법
|
|
US20160075772A1
(en)
|
2014-09-12 |
2016-03-17 |
Regeneron Pharmaceuticals, Inc. |
Treatment of Fibrodysplasia Ossificans Progressiva
|
|
WO2016168613A1
(en)
|
2015-04-15 |
2016-10-20 |
Regeneron Pharmaceuticals, Inc. |
Methods of increasing strength and functionality with gdf8 inhibitors
|
|
WO2018009732A1
(en)
|
2016-07-08 |
2018-01-11 |
Regeneron Pharmaceuticals, Inc. |
Anti-activin a antibodies and methods of use thereof for treating pulmonary arterial hypertension
|